Jain Deepanshu, Desai Aakash, Mahmood Ejaz, Singhal Shashideep
Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA (Deepanshu Jain, Ejaz Mahmood).
Division of Gastroenterology, Hepatology and Nutrition, University of Texas Health Science Center at Houston, Houston, Texas (Aakash Desai, Shashideep Singhal), USA.
Ann Gastroenterol. 2017;30(3):262-272. doi: 10.20524/aog.2017.0128. Epub 2017 Feb 10.
The management of incidentally discovered small upper gastrointestinal (GI) tract submucosal tumors (SMT) remains debatable. In this review, we summarize the evolving experience with submucosal tunneling endoscopic resection (STER) of upper GI SMTs originating from the muscularis propria. From 16 original studies, we reviewed a total of 703 patients with 736 lesions. Of these, 436 were located in the esophagus, 146 in the esophagogastric junction (EGJ) and 154 in the stomach. The composite complete resection rate (CRR) for STER of upper GI tumors arising from the muscularis propria layer was 99.8% (445/446). The composite CRR for STER of esophageal, EGJ and gastric SMTs arising from the muscularis propria layer was 100% (208/208),100% (78/78)and 100% (115/115), respectively. The composite resection rate (EBRR) for STER of upper GI tumors arising from the muscularis propria layer was 94.6% (679/718). The composite EBRR for STER of esophageal, EGJ and gastric SMTs arising from the muscularis propria layer was 98.6% (205/208), 96.2% (75/78) and 97.9% (95/97), respectively. Tumor recurrence rate was 0%. The reported complication rate for STER was high but the majority responded to conservative management. STER is a minimally invasive and efficacious alternative to surgery, especially for patients with small tumors (<3 cm). Careful selection of candidates remains crucial for excluding potentially malignant tumors.
偶然发现的上消化道(GI)小黏膜下肿瘤(SMT)的管理仍存在争议。在本综述中,我们总结了源于固有肌层的上消化道SMT的黏膜下隧道内镜切除术(STER)的不断发展的经验。从16项原始研究中,我们共回顾了703例患者的736个病变。其中,436个位于食管,146个位于食管胃交界(EGJ),154个位于胃。源于固有肌层的上消化道肿瘤STER的综合完全切除率(CRR)为99.8%(445/446)。源于固有肌层的食管、EGJ和胃SMT的STER综合CRR分别为100%(208/208)、100%(78/78)和100%(115/115)。源于固有肌层的上消化道肿瘤STER的综合切除率(EBRR)为94.6%(679/718)。源于固有肌层的食管、EGJ和胃SMT的STER综合EBRR分别为98.6%(205/208)、96.2%(75/78)和97.9%(95/97)。肿瘤复发率为0%。报道的STER并发症发生率较高,但大多数通过保守治疗得到缓解。STER是一种微创且有效的手术替代方法,尤其适用于小肿瘤(<3 cm)患者。仔细选择候选者对于排除潜在恶性肿瘤仍然至关重要。